Table 1.

Clinical characteristics of a series of 14 patients deceased after COVID-19 infection

Patient No.	Age, years	Sex	BMI, kg/m2	Main treatment	Secondary infections	Hospitalization time, days	Death-to-autopsy delay, h
1	83	M	21.4	Amoxicillin	−	5	4
2	54	M	27.0	Hydroxychloroquine, ceftazidime, meropenem	Pseudomonas aeruginosa	17	18
3	73	M	25.6	Hydroxychloroquine, acetylsalicylic acid	−	12	36
4	71	F	27.2	Cefuroxime, amiodarone	Escherichia coli	20	4
5	54	M	37.8	Hydroxychloroquine, cefuroxime	Haemophilus	24	8
6	64	M	39.8	Hydroxychloroquine, oxacillin	Staphylococcus aureus	12	17
7	56	M	29.8	Hydroxychloroquine, amoxicillin, ciprofloxacin	S. aureus, Haemophilus	21	73
8	55	M	39.9	Hydroxychloroquine, ceftazidime, vancomycin	S. aureus	28	62
9	51	F	28.3	Hydroxychloroquine	HCV	15	15
10	77	M	29.5	Ciprofloxacin, vancomycin	Bacteroides diastonis	34	8
11	81	F	27.9	Hydroxychloroquine, cefuroxime	Haemophilus	14	2.5
12	59	M	33.0	Hydroxychloroquine, oxacillin, ciprofloxacin, flucloxacillin, ceftazidime, acyclovir, ganciclovir, temocillin, vancomycin	Enterobacter, HSV1, S. aureus, Pseudomonas	36	3.5
13	50	F	49.8	Darunavir, emtricitabine, tenofovir, chloroquine, hydroxychloroquine, Ciproxin	HIV, Enterobacter aerogenes	52	24
14	58	M	31.0	Ciprofloxacin, vancomycin	B. diastonis	42	9

BMI, body mass index; F, female; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV1, herpes simplex virus 1; M, male.